J&J grows cancer drug portfolio with newly approved bispecific
BioPharma
Source: biopharmadive.com
Page 4 - Peter Lebowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Lebowitz Today - Breaking & Trending Today
Phase 3 Trial Results With Amivantamab-vmjw Suggest Benefits for Patients With NSCLC, EGFR Mutations
Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.
Source: pharmacytimes.com
Combination of Rybrevant and Chemotherapy Improves Survival for Some Patients with NSCLC
The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.
Source: curetoday.com
Confirmatory PAPILLON Study Supports Amivantamab-vmjw For Patients with Severe Lung Cancer Mutation
The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.
Source: pharmacytimes.com
Janssen seeks US FDA approval of new indication for Carvykti
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking approval of a new indication for Carvykti from the FDA.